Increased long noncoding RNA LINP1 expression and its prognostic significance in human breast cancer.
Mounting evidence suggests that the long noncoding RNAs (lncRNAs) function in multiple cancers. Dysregulation of lncRNA in non-homologous end joining (NHEJ) pathway 1 (LINP1) has been reported in breast cancer. However, its clinical significance in breast cancer remains unclear. The aim of this study was to investigate the prognostic relevance of LINP1 in breast cancer. Expression of LINP1 in tumor and their matched non-tumor tissues was determined by quantitative Real Time-PCR (qRT-PCR) in breast cancer patients. The relevance of LINP1 expression to the clinicopathological factors was assessed. Kaplan-Meier analysis was performed to evaluate the overall survival and disease-free survival of breast cancer patients with the expression level of LINP1. Cox proportional hazard regression analysis was performed at both univariate and multivariate levels. The results showed that LINP1 appeared to have higher expression in breast cancer tissues than in adjacent non-tumor tissues (p < 0.01). Increased expression of LINP1 was correlated with advanced TNM stage (p = 0.002), more lymph node metastasis (p = 0.000), and poorer pathological differentiation (p = 0.004). Furthermore, clinical assay indicated that patients with high LINP1 expression had a shorter overall survival and disease-free survival compared with the low LINP1 expression group. Finally, Cox regression analysis showed that LINP1 expression was an independent prognosis-predicting factor for breast cancer patients. LncRNA-LINP1 may be involved in the progression of the breast cancer and be a novel indicator of poor prognosis in patients with breast cancer.